JP2015511217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511217A5 JP2015511217A5 JP2014552503A JP2014552503A JP2015511217A5 JP 2015511217 A5 JP2015511217 A5 JP 2015511217A5 JP 2014552503 A JP2014552503 A JP 2014552503A JP 2014552503 A JP2014552503 A JP 2014552503A JP 2015511217 A5 JP2015511217 A5 JP 2015511217A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- heterocyclyl
- alkyl
- optionally substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1,2,3,4-tetrahydroquinolin-2-yl Chemical group 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000004246 indolin-2-yl group Chemical group [H]N1C(*)=C([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 102100004121 IDH1 Human genes 0.000 claims 3
- 101700024037 IDH1 Proteins 0.000 claims 3
- 101700066748 IDH3B Proteins 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102200069708 IDH1 R132C Human genes 0.000 claims 1
- 102200069690 IDH1 R132H Human genes 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002071 myeloproliferative Effects 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 *C(C(N*)=O)N(*)C(*)O Chemical compound *C(C(N*)=O)N(*)C(*)O 0.000 description 1
- ZUEUSJZREMFTLS-UHFFFAOYSA-N CC(C(C1)CC1(F)F)[F]C1CC(C)C1 Chemical compound CC(C(C1)CC1(F)F)[F]C1CC(C)C1 ZUEUSJZREMFTLS-UHFFFAOYSA-N 0.000 description 1
- NBSJCAVRXHCOAD-UHFFFAOYSA-N CC(CC1)CC1(F)F Chemical compound CC(CC1)CC1(F)F NBSJCAVRXHCOAD-UHFFFAOYSA-N 0.000 description 1
- CDGCGIDIKQPXSQ-UHFFFAOYSA-N CC(CCCC1)C1(F)F Chemical compound CC(CCCC1)C1(F)F CDGCGIDIKQPXSQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012070607 | 2012-01-19 | ||
| CNPCT/CN2012/070607 | 2012-01-19 | ||
| PCT/CN2013/070755 WO2013107405A1 (en) | 2012-01-19 | 2013-01-21 | Therapeutically active compounds and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017198488A Division JP2018021072A (ja) | 2012-01-19 | 2017-10-12 | 治療活性化合物およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511217A JP2015511217A (ja) | 2015-04-16 |
| JP2015511217A5 true JP2015511217A5 (US07794700-20100914-C00152.png) | 2017-10-12 |
| JP6228130B2 JP6228130B2 (ja) | 2017-11-08 |
Family
ID=48798662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552503A Expired - Fee Related JP6228130B2 (ja) | 2012-01-19 | 2013-01-21 | 治療活性化合物およびそれらの使用方法 |
| JP2017198488A Withdrawn JP2018021072A (ja) | 2012-01-19 | 2017-10-12 | 治療活性化合物およびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017198488A Withdrawn JP2018021072A (ja) | 2012-01-19 | 2017-10-12 | 治療活性化合物およびそれらの使用方法 |
Country Status (8)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010105243A1 (en) | 2009-03-13 | 2010-09-16 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| US8785450B2 (en) | 2009-06-29 | 2014-07-22 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
| PL3406251T3 (pl) | 2011-05-03 | 2024-04-29 | Agios Pharmaceuticals, Inc. | Aktywatory kinazy pirogronianowej do stosowania w terapii |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| SI2800743T1 (en) | 2012-01-06 | 2018-08-31 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and methods for their use |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| WO2014062511A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015010297A1 (en) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| KR101861869B1 (ko) * | 2013-09-10 | 2018-05-28 | 경희대학교 산학협력단 | 신규한 비스-아미드 유도체 및 이의 용도 |
| CN103694142A (zh) * | 2013-11-28 | 2014-04-02 | 浙江科技学院 | 4-N-Boc-氨基环己酮的制备方法 |
| KR102400737B1 (ko) | 2014-03-14 | 2022-05-20 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
| RU2692782C2 (ru) | 2014-10-01 | 2019-06-27 | Дайити Санкио Компани, Лимитед | Производное изоксазола в качестве ингибитора мутантной изоцитратдегидрогеназы 1 |
| CA2965201A1 (en) * | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| EP3226690B1 (en) * | 2014-12-05 | 2020-05-20 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| WO2016201227A1 (en) | 2015-06-11 | 2016-12-15 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| EP4403173A3 (en) | 2015-10-15 | 2024-10-09 | Les Laboratoires Servier | Combination therapy for treating malignancies |
| MD3362066T2 (ro) | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Terapie combinată pentru tratamentul tumorilor maligne |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| CN109071429B (zh) * | 2016-03-22 | 2021-04-02 | 正大天晴药业集团股份有限公司 | 丙啶磺酰胺类化合物及其使用方法 |
| CA3018649A1 (en) | 2016-03-22 | 2017-09-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Sultam compound and application method thereof |
| MX2019010108A (es) * | 2017-02-28 | 2020-01-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivados de azetidina. |
| CA3076405A1 (en) | 2017-09-22 | 2019-03-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline sulfamide compound |
| CN107827880B (zh) * | 2017-10-17 | 2020-05-22 | 浙江工业大学上虞研究院有限公司 | 一种含咪唑和1,3,4-噁二唑结构的甲腈类化合物及其制备方法和应用 |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| CN109535025B (zh) * | 2018-12-18 | 2022-09-09 | 尚科生物医药（上海）有限公司 | 一种艾伏尼布中间体3,3-二氟环丁胺盐酸盐的制备方法 |
| WO2020127887A1 (en) * | 2018-12-21 | 2020-06-25 | Sandoz Ag | Process for the preparation of an intermediate product of ivosidenib |
| US20230242503A9 (en) * | 2019-08-09 | 2023-08-03 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
| TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
| WO2022026565A1 (en) * | 2020-07-29 | 2022-02-03 | Ideaya Biosciences, Inc. | Cyclized acetamido derivatives as dna polymerase theta inhibitors |
| WO2022043465A1 (en) * | 2020-08-26 | 2022-03-03 | Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Inhibitors of no production |
| WO2023241322A1 (en) * | 2022-06-16 | 2023-12-21 | Danatlas Pharmaceuticals Co., Ltd. | Heterocyclic derivatives, compositions and uses thereof |
| WO2024153143A1 (zh) * | 2023-01-18 | 2024-07-25 | 中国药科大学 | 含氮并环类化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9064598A (en) * | 1998-07-10 | 2000-02-01 | Harald Groger | Precusors for pna-monomers |
| KR20050036293A (ko) * | 2003-10-15 | 2005-04-20 | 동아제약주식회사 | 나프토퀴논계 화합물을 함유한 세포질형 이소시트릭산탈수소화효소 활성 저해제 및 비만과 고지혈증 예방 또는치료용 약학적 조성물 |
| FR2932483A1 (fr) * | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
| JP6081354B2 (ja) * | 2010-07-16 | 2017-02-15 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療活性組成物およびそれらの使用方法 |
| US9474779B2 (en) * | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US20150031627A1 (en) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
-
2013
- 2013-01-21 MX MX2014008737A patent/MX350432B/es active IP Right Grant
- 2013-01-21 WO PCT/CN2013/070755 patent/WO2013107405A1/en active Application Filing
- 2013-01-21 JP JP2014552503A patent/JP6228130B2/ja not_active Expired - Fee Related
- 2013-01-21 EP EP13738187.7A patent/EP2804850B1/en active Active
- 2013-01-21 CA CA2860858A patent/CA2860858A1/en not_active Abandoned
- 2013-01-21 ES ES13738187T patent/ES2698625T3/es active Active
- 2013-01-21 US US14/373,154 patent/US20150087600A1/en not_active Abandoned
-
2015
- 2015-05-20 HK HK15104811.2A patent/HK1204319A1/xx not_active IP Right Cessation
-
2016
- 2016-06-29 US US15/196,842 patent/US20160304556A1/en not_active Abandoned
-
2017
- 2017-10-12 JP JP2017198488A patent/JP2018021072A/ja not_active Withdrawn
